EHA 2015: Overall survival after adjustment for crossover in a study of idelalisib with rituximab for relapsed CLL - 101793

Spotlight
Video

EHA 2015: Overall survival after adjustment for crossover in a study of idelalisib with rituximab for relapsed CLL

VJHemOnc has 1040 videos Subscribe Here

Loading........
Description: At the 20th Congress of the European Hematology Association (EHA), Paolo Ghia, MD, PhD, of Università Vita-Salute San Raffaele, Milan, Italy, discusses the overall survival analysis adjusting for treatment effect after crossover in a phase 3 study evaluating the PI3K delta inhibitor, idelalisib, in combination with rituximab in patients with relapsed chronic lymphocytic leukemia (CLL).

—————

The Video Journal of Hematological Oncology (VJHemOnc) is an independent, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve understanding and awareness of hematological malignancies.

Website: http://www.vjhemonc.com/...
Twitter: https://twitter.com/VJHemOn...
Facebook: https://www.facebook.com/vj...
LinkedIn: https://www.linkedin.com/co...
Shared By : VJHemOnc
Posted on : 07/22/15
Added : 3 years ago